Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

The Lancet Oncology

Volumn 18, Issue 8, 2017, Pages 1009-1021

  Turajlic, Samra ^a,b   Litchfield, Kevin ^a   Xu, Hang ^a   Rosenthal, Rachel ^d   McGranahan, Nicholas ^a,d   Reading, James L ^c   Wong, Yien Ning S ^c   Rowan, Andrew ^a   Kanu, Nnennaya ^d   Al Bakir, Maise ^a   Chambers, Tim ^a   Salgado, Roberto ^e,f   Savas, Peter ^f   Loi, Sherene ^f   Birkbak, Nicolai J ^a   Sansregret, Laurent ^a   Gore, Martin ^b   Larkin, James ^b   Quezada, Sergio A ^c   Swanton, Charles ^a,d,g  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Imperial College Hammersmith Campus   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; DNA;

ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CANCER RESEARCH; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; COMPUTER MODEL; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INDEL MUTATION; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RNA SEQUENCE; SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UPREGULATION; WHOLE EXOME SEQUENCING; DNA MUTATIONAL ANALYSIS; EXOME; FRAMESHIFT MUTATION; GENE; GENETIC DATABASE; GENETICS; GENOMICS; IMMUNOLOGY; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM; RENAL CELL CARCINOMA;

ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXOME; FRAMESHIFT MUTATION; GENES, CDC; GENOMICS; HUMANS; INDEL MUTATION; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASMS; PHENOTYPE; UP-REGULATION;

EID: 85022069589     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30516-8     Document Type: Article

References (72)

1. Gubin, MM, Artyomov, MN, Mardis, ER, Schreiber, RD, Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125 (2015), 3413–3421.
2. Cancer Genome Atlas Research, Weinstein, JN, Collisson, EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45 (2013), 1113–1120.
3. Yang, H, Zhong, Y, Peng, C, Chen, JQ, Tian, D, Important role of indels in somatic mutations of human cancer genes. BMC Med Genet, 11, 2010, 128.
4. Tran, E, Robbins, PF, Rosenberg, SA, ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18 (2017), 255–262.
5. Gubin, MM, Zhang, X, Schuster, H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
6. van Rooij, N, van Buuren, MM, Philips, D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31 (2013), e439–e442.
7. Robbins, PF, Lu, YC, El-Gamil, M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19 (2013), 747–752.
8. Prickett, TD, Crystal, JS, Cohen, CJ, et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol Res 4 (2016), 669–678.
9. Tran, E, Robbins, PF, Lu, YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375 (2016), 2255–2262.
10. Alexandrov, LB, Nik-Zainal, S, Wedge, DC, et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
11. Linnemann, C, van Buuren, MM, Bies, L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 21 (2015), 81–85.
12. Van Allen, EM, Miao, D, Schilling, B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
13. Snyder, A, Makarov, V, Merghoub, T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
14. Rizvi, NA, Hellmann, MD, Snyder, A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
15. Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
16. Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
17. Senbabaoglu, Y, Gejman, RS, Winer, AG, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol, 17, 2016, 231.
18. Gore, ME, Griffin, CL, Hancock, B, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375 (2010), 641–648.
19. McDermott, DF, Cheng, SC, Signoretti, S, et al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21 (2015), 561–568.
20. McDermott, DF, Sosman, JA, Sznol, M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase IA study. J Clin Oncol 34 (2016), 833–842.
21. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
22. Linnebacher, M, Gebert, J, Rudy, W, et al. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93 (2001), 6–11.
23. Sato, Y, Yoshizato, T, Shiraishi, Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45 (2013), 860–867.
24. Gerlinger, M, Horswell, S, Larkin, J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46 (2014), 225–233.
25. Hugo, W, Zaretsky, JM, Sun, L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 168, 2017, 542.
26. Jamal-Hanjani, M, Wilson, GA, McGranahan, N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376 (2017), 2109–2121.
27. McKenna, A, Hanna, M, Banks, E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20 (2010), 1297–1303.
28. Li, H, Durbin, R, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
29. Li, H, Handsaker, B, Wysoker, A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25 (2009), 2078–2079.
30. Koboldt, DC, Zhang, Q, Larson, DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22 (2012), 568–576.
31. Cibulskis, K, Lawrence, MS, Carter, SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31 (2013), 213–219.
32. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499 (2013), 43–49.
33. Lindeboom, RG, Supek, F, Lehner, B, The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet 48 (2016), 1112–1118.
34. Roth, A, Khattra, J, Yap, D, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods 11 (2014), 396–398.
35. Van Loo, P, Nordgard, SH, Lingjaerde, OC, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 107 (2010), 16910–16915.
36. Rooney, MS, Shukla, SA, Wu, CJ, Getz, G, Hacohen, N, Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
37. Shukla, SA, Rooney, MS, Rajasagi, M, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 33 (2015), 1152–1158.
38. Saunders, CT, Wong, WS, Swamy, S, Becq, J, Murray, LJ, Cheetham, RK, Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28 (2012), 1811–1817.
39. Nielsen, M, Lundegaard, C, Blicher, T, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One, 2, 2007, e796.
40. Jamal-Hanjani, M, Wilson, GA, McGranahan, N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376 (2017), 2109–2121.
41. Giannakis, M, Mu, XJ, Shukla, SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep, 17, 2016, 1206.
42. Fritsch, EF, Rajasagi, M, Ott, PA, Brusic, V, Hacohen, N, Wu, CJ, HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2 (2014), 522–529.
43. McGranahan, N, Furness, AJ, Rosenthal, R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
44. Nanda, R, Chow, LQ, Dees, EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34 (2016), 2460–2467.
45. Nolan, E, Savas, P, Policheni, AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med, 2017, 10.1126/scitranslmed.aal4922 published online June 7.
46. Streisinger, G, Okada, Y, Emrich, J, et al. Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday. Cold Spring Harb Symp Quant Biol 31 (1966), 77–84.
47. Furney, SJ, Turajlic, S, Stamp, G, et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment Cell Melanoma Res 27 (2014), 835–838.
48. Therkildsen, C, Joost, P, Lindberg, LJ, Ladelund, S, Smith-Hansen, L, Nilbert, M, Renal cell cancer linked to Lynch syndrome: increased incidence and loss of mismatch repair protein expression. Int J Urol 23 (2016), 528–529.
49. Miuma, S, Saldivar, JC, Karras, JR, et al. Fhit deficiency-induced global genome instability promotes mutation and clonal expansion. PLoS One, 8, 2013, e80730.
50. Cancer Genome Atlas Research N, Linehan, WM, Spellman, PT, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374 (2016), 135–145.
51. Davis, CF, Ricketts, CJ, Wang, M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26 (2014), 319–330.
52. Scelo, G, Riazalhosseini, Y, Greger, L, et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun, 5, 2014, 5135.
53. Kuroda, K, Hibi, D, Ishii, Y, et al. Ochratoxin A induces DNA double-strand breaks and large deletion mutations in the carcinogenic target site of gpt delta rats. Mutagenesis 29 (2014), 27–36.
54. Margulis, V, Lin, J, Yang, H, Wang, W, Wood, CG, Wu, X, Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway. Cancer Epidemiol Biomarkers Prev 17 (2008), 2366–2373.
55. Wang, Y, Cortez, D, Yazdi, P, Neff, N, Elledge, SJ, Qin, J, BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14 (2000), 927–939.
56. Maby, P, Tougeron, D, Hamieh, M, et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res 75 (2015), 3446–3455.
57. Chow, S, Galvis, V, Pillai, M, et al. High-dose interleukin2—a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. J Immunother Cancer, 4, 2016, 67.
58. Geynisman, DM, Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 68 (2015), 912–914.
59. Ruiz-Banobre, J, Anido, U, Abdulkader, I, Antunez-Lopez, J, Lopez-Lopez, R, Garcia-Gonzalez, J, Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report. Front Oncol, 6, 2016, 250.
60. SP D'Angelo, Larkin, J, Sosman, JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35 (2017), 226–235.
61. Furney, SJ, Turajlic, S, Stamp, G, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230 (2013), 261–269.
62. Lappalainen, T, Sammeth, M, Friedlander, MR, et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501 (2013), 506–511.
63. Wang, D, Zavadil, J, Martin, L, et al. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Biol 31 (2011), 3670–3680.
64. Huang, J, El-Gamil, M, Dudley, ME, Li, YF, Rosenberg, SA, Robbins, PF, T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 172 (2004), 6057–6064.
65. Maby, P, Galon, J, Latouche, JB, Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. Oncoimmunology, 5, 2016, e1115943.
66. Schwitalle, Y, Kloor, M, Eiermann, S, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134 (2008), 988–997.
67. Williams, DS, Bird, MJ, Jorissen, RN, et al. Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS One, 5, 2010, e16012.
68. Le, DT, Durham, JN, Smith, KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 10.1126/science.aan6733 published online June 8.
69. Lai, J, Zhou, Z, Tang, XJ, Gao, ZB, Zhou, J, Chen, SQ, A tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma. Int J Mol Sci, 2016, 10.3390/ijms17050739 published online May 14.
70. Wherry, EJ, Kurachi, M, Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15 (2015), 486–499.
71. Duan, F, Duitama, J, Al Seesi, S, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 211 (2014), 2231–2248.
72. Ruark, E, Munz, M, Clarke, M, et al. OpEx—a validated, automated pipeline optimised for clinical exome sequence analysis. Sci Rep, 6, 2016, 31029.